American Century Companies Inc. Increases Stake in Solventum Co. (NYSE:SOLV)

American Century Companies Inc. lifted its position in shares of Solventum Co. (NYSE:SOLV - Free Report) by 43.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 146,608 shares of the company's stock after purchasing an additional 44,251 shares during the quarter. American Century Companies Inc. owned 0.08% of Solventum worth $9,685,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Modus Advisors LLC purchased a new position in shares of Solventum during the fourth quarter valued at approximately $25,000. Stonebridge Financial Group LLC bought a new position in Solventum during the 4th quarter valued at $26,000. Crews Bank & Trust purchased a new position in Solventum during the 4th quarter worth $32,000. Synergy Asset Management LLC purchased a new position in Solventum during the 4th quarter worth $35,000. Finally, Spire Wealth Management purchased a new stake in shares of Solventum in the fourth quarter valued at about $37,000.

Solventum Trading Down 5.7 %

NYSE:SOLV traded down $3.97 during mid-day trading on Friday, reaching $66.22. 1,873,221 shares of the company's stock traded hands, compared to its average volume of 1,370,900. The company has a 50 day moving average price of $75.60 and a 200-day moving average price of $71.99. The firm has a market capitalization of $11.45 billion and a price-to-earnings ratio of 24.08. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $85.92.

Remove Ads

Wall Street Analysts Forecast Growth

SOLV has been the topic of several recent analyst reports. Mizuho lifted their target price on shares of Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a research report on Monday, March 3rd. Wells Fargo & Company lifted their price target on Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a report on Friday, February 28th. The Goldman Sachs Group upped their price objective on Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a research note on Monday, March 3rd. Bank of America lifted their target price on Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 26th. Finally, Morgan Stanley increased their price target on shares of Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a research report on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, Solventum currently has an average rating of "Hold" and an average price target of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.